STOCK TITAN
  1. Home
  2. Sec-filings
  3. RGNT
  4. [Form 4] REGENTIS BIOMATERIALS LTD. Insider Trading Activity

Director Ben-Elazar Pini awarded Regentis Biomaterials (RGNT) stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Regentis Biomaterials director Ben-Elazar Pini received two employee stock option grants covering 8,313 and 24,826 ordinary shares. The options have exercise prices of 0.0030 and 2.1600 per share; one grant is fully vested, while the other vests quarterly through June 4, 2029 under the 2024 Share Option Plan.

Positive

  • None.

Negative

  • None.
Insider Ben-Elazar Pini
Role Director
Type Security Shares Price Value
Grant/Award Employee Stock Option (Right to Buy) 24,826 $0.00 --
Grant/Award Employee Stock Option (Right to Buy) 8,313 $0.00 --
Holdings After Transaction: Employee Stock Option (Right to Buy) — 24,826 shares (Direct)
Footnotes (1)
  1. This option grant was approved by the Board of Directors of the Issuer on June 4, 2026, subject to shareholder approval, which was obtained on July 9, 2026. This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on September 4, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or June 4, 2029. This option grant was approved by the Board of Directors of the Issuer on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026. This option grant is fully vested as of this date. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2024 Share Option Plan must be registered in the name of a trustee.
Options granted (first grant) 8,313 shares Employee stock options granted to director Ben-Elazar Pini, fully vested as of July 9, 2026
Exercise price (first grant) 0.0030 per share Conversion or exercise price for 8,313 employee stock options over ordinary shares
Options granted (second grant) 24,826 shares Employee stock options vesting in 1/12 increments quarterly until June 4, 2029
Exercise price (second grant) 2.1600 per share Conversion or exercise price for 24,826 employee stock options over ordinary shares
Employee Stock Option (Right to Buy) financial
"security title "Employee Stock Option (Right to Buy)" granted to the director"
Section 102 of the Israeli Tax Ordinance regulatory
"tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee"
2024 Share Option Plan financial
"in connection with the Issuer's 2024 Share Option Plan must be registered"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transaction did Ben-Elazar Pini report for Regentis Biomaterials (RGNT)?
Ben-Elazar Pini reported receiving two employee stock option grants at Regentis Biomaterials. These derivative awards cover underlying 8,313 and 24,826 ordinary shares, reflecting equity-based compensation rather than any open-market share purchases or sales.

How many stock options were granted to Ben-Elazar Pini at RGNT and at what exercise prices?
Pini was granted 8,313 options with an exercise price of 0.0030 per share and 24,826 options with an exercise price of 2.1600 per share. Each option corresponds to one underlying ordinary share of Regentis Biomaterials.

What is the vesting schedule for the 24,826 Regentis Biomaterials (RGNT) options?
The 24,826 options vest on a quarterly schedule. One-twelfth (1/12) vests on September 4, 2026, with an additional one-twelfth vesting on the last day of each subsequent three-month period until full vesting on June 4, 2029.

Are any of Ben-Elazar Pini’s new Regentis Biomaterials (RGNT) options already fully vested?
Yes. The grant covering 8,313 underlying ordinary shares is described as fully vested as of the transaction date. This means those options are immediately exercisable, subject to their stated exercise price and expiration date in 2036.

How does Section 102 of the Israeli Tax Ordinance affect these RGNT option grants?
The filing notes that to qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the 2024 Share Option Plan must be registered in the name of a trustee, a structural requirement for these employee equity awards.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ben-Elazar Pini
(Last)(First)(Middle)
C/O REGENTIS BIOMATERIALS LTD.
60 MEDINAT HAYHEHUDIM
(Street)
HERZLIYA4676652
(City)(State)(Zip)
ISRAEL
(Country)		2. Issuer Name and Ticker or Trading Symbol
REGENTIS BIOMATERIALS LTD. [ RGNT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (Right to Buy)(1)(2)(5)$2.1607/09/2026A24,82609/04/202606/04/2036Ordinary Shares24,826$024,826D
Employee Stock Option (Right to Buy)(3)(4)(5)$0.00307/09/2026A8,31302/23/202602/23/2036Ordinary Shares8,313$08,313D
Explanation of Responses:
1. This option grant was approved by the Board of Directors of the Issuer on June 4, 2026, subject to shareholder approval, which was obtained on July 9, 2026.
2. This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on September 4, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or June 4, 2029.
3. This option grant was approved by the Board of Directors of the Issuer on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026.
4. This option grant is fully vested as of this date.
5. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2024 Share Option Plan must be registered in the name of a trustee.
/s/ Pini Ben-Elazar07/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR